Objectives: To establish the susceptibility of Enterococcus faecium isolates from pigs and chickens to antimicrobial growth promoters that either were or had been in use in the European Union.
Introduction
Enterococci in the normal faecal flora of animals have been widely accepted as indicator bacteria for the detection of the prevalence of resistance due to the use of growth-promoting antimicrobial agents. [1] [2] [3] Enterococcus faecalis and Enterococcus faecium are found commonly in animals and humans, but the latter is the more useful indicator since it is considered a more significant resistance gene reservoir for the anti-Gram-positive antibiotic classes used as growth promoters in animals and as therapeutic agents in humans.
Data have been published from individual countries such as Denmark, 1 Sweden 2 and The Netherlands 3 showing the susceptibility of E. faecium isolated from farm animals, but an international centralized study comparing the susceptibility patterns in different countries has not hitherto been attempted. This study was set up to establish the susceptibility, over a 2 year period, of E. faecium to seven growth-promoting antimicrobial agents widely used in the early 1990s in Europe. Identical sampling protocols were used in six different EU countries and in two host species, and a single laboratory carried out susceptibility testing, to overcome the technical variations that might occur between laboratories. Seven growth-promoting antibiotics were tested in this study (Table 1) . Six of them were available for use in chickens and swine throughout the EU in 1998 (with the exception of certain Scandinavian countries) although one compound, avoparcin (a glycopeptide), had already been withdrawn within the EU. Unexpectedly, after the first year's samples had been collected, but prior to the second year of the study, four others, bacitracin (a polypeptide), spiramycin, tylosin (macrolides) and virginiamycin (a streptogramin), were banned as of July 1999. The removal of the four compounds provided an opportunity to follow the early effects of such removal on the antimicrobial susceptibility of E. faecium in the two host species. The other two compounds tested were avilamycin (an orthosomycin) and flavophospholipol (a glycophospholipid). These latter two compounds were available through both years of the study (but are to be withdrawn in the EU from 1 January 2006).
Methods
During successive 1 year periods (July 1998-June 1999: year 1; and September 1999-August 2000: year 2) samples were taken from chickens and pigs in four EU countries for each species. Denmark, The Netherlands, Spain, and Sweden were chosen for pigs, and France, The Netherlands, Sweden and the UK for poultry. Sampling coordinators in each country selected at least four abattoirs and four poultry-processing plants (excluding those that serviced only 'organic' systems). The sites chosen were geographically spread to be representative of the main animal-producing areas. Samples of colonic contents from pigs and caeca from chickens were collected randomly at the time of slaughter, with only one sample from each flock or herd, and sent to selected national microbiology laboratories in the country in which they were taken. There samples were homogenized, diluted and inoculated on Slanetz and Bartley agar, a selective, differential medium for enterococci, and incubated at 42 C for 48 h. Up to three colonies with the distinctive morphology of E. faecium were subcultured and their identity confirmed by a simplified scheme 4 based on the work of Devriese et al., 5 modified by the addition of a test for methyl-a-D-glucopyranosidase. 6 The tests and the expected results for E. faecium were as follows: tetrazolium chloride reduction (-), acid from ribose and mannitol (+) and aesculin hydrolysis (+), and for confirmation in cases of doubt, motility (-), pigmentation (-) and acid from methyl-a-D-glucopyranoside (-). One isolate of E. faecium per specimen was stored at -70 C (or as a default, as a slope or stab culture on tryptone soya agar). For each country, the target number of isolates was 300 per host animal-in total 1200 isolates per host species per year. Isolates were transported in batches to the laboratories of Inveresk Research, Tranent, Scotland. There, after isolates with yellow colonies had been rejected, the identity of a proportion of the rest was reconfirmed either by the use of commercial identification kits [API 20 Strep or rapid ID 32 Strep, (bioMérieux, Basingstoke, UK)] or by a PCR method 7 as later corrected. 8 The primers for the PCR, EfeddlF1 (5 0 +GCAAGGCTTCTTAGAGA 3 0 ) and EfeddlF2 (3 0 -CATCGT-GTAAGCTAACTTC 5 0 ) were supplied by PE-Applied Biosystems (Beaconsfield, UK) at a concentration of 1 mg/mL. Briefly, the conditions for PCR were as follows. Samples were prepared by the addition of a large loopful of pure overnight culture to 500 mL distilled water in an Eppendorf tube. This was then placed in a thermocycler at 100 C for 10 min and then held at -70 C. Before use, the tube was spun at 9000g for 2 min and the supernatant was added to 50 mL of reaction mix, which consisted of 37.4 mL of dH 2 O, 10 mL of 10 · PCR buffer (200 mM Tris pH 9.0, 1 M KCl 0.2 mg/mL gelatine), 0.7 mL of Efeddl F1, 0.7 mL of Efeddl F2, 0.8 mL of dNTP mixture (Pharmacia, Milton Keynes, UK) and 0.4 mL of Taq polymerase 250 U (Boehringer Mannheim GmbH, Germany). Tubes were placed in a Hybaid Omnigene Thermocycler and heated as follows: one cycle of 2 min at 94 C, followed by 35 cycles of 1 min at 94 C, 1 min at 54 C and 1 min at 72 C, and one cycle of 10 min at 72 C. Samples were stored at -20 C pending analysis. PCR product (10 mL) + 2 mL of 5 · loading dye was added to a 3% agarose gel with fX174 HaeIII markers and run at 150 mA for 1 h. The presence of a band of 550 bp in length (subject to the correct performance of negative and positive controls) indicated that the organism was E. faecium.
Minimum inhibitory concentrations of the following antibiotics obtained from their manufacturers were determined by agar dilution as described by the National Committee for Clinical Laboratory Standards (NCCLS, now re-named Clinical and Laboratory Standards Institute CLSI) document M7-A4: 9 ampicillin (for quality control purposes), avilamycin (Eli Lilly), avoparcin (Roche), bacitracin (Alpharma), flavophospholipol (Hoechst Roussel Vet), spiramycin (Rhone Poulenc Rorer), tylosin (Eli Lilly) and virginiamycin (Pfizer). The following bacteria were used for quality control: E. faecium ATCC6569, E. faecalis ATCC29212 and Staphylococcus aureus ATCC29213. Although QC values were not available for any of the growth-promoting agents tested, these were generated in the course of the investigation as study-specific quality control ranges. Ampicillin, for which QC values were available, was used to ensure general test validity.
MIC data for each antimicrobial were then tabulated by year, by host animal and by country. Distributions of MICs were determined for each antibiotic and for QC strains, and on this basis the range of susceptibility of the wild-type population was defined for each antibiotic. This wild-type population was labelled 'susceptible' while other populations were defined as 'resistant', having low-level or high-level microbiological resistance as defined by the European Committee for Antimicrobial Susceptibility Testing (EUCAST, http://www.eucast. org) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). 10, 11 It is emphasized that assigned breakpoints were microbiological, and differed in principle from those used for animal or human therapy, which must also take into account pharmacological parameters and clinical and microbiological results of treatment.
9 'Associated resistance' was identified when bacterial isolates resistant to one antibiotic were significantly more often resistant to a second antibiotic than were susceptible isolates.
The statistical significances of differences in the prevalence of resistance rates were assessed by Fisher's exact test (two-tailed) by the method of summing of small values (http://www.graphpad.com/ quickcalcs/CatMenu.cfm).
Results

Submitted isolates of E. faecium
During year 1 and year 2, respectively, 2353 and 2137 isolates of E. faecium were submitted to the central susceptibility testing laboratory. Of this total, 181 (4.1%) were rejected on the basis of phenotypic or PCR results. Of the remaining 4309 isolates, a further 635 selected at random were confirmed as E. faecium by PCR. The antimicrobial susceptibility of the remaining 4309 isolates was determined.
Antimicrobial susceptibility
Quality control strains. The quality control ranges established during the course of the investigation are shown in Table 2 . Although the NCCLS Antimicrobial Susceptibility Testing Subcommittee 12 has established procedures to derive multi-laboratory quality control ranges for therapeutic antibiotics, there were no values available to use for these antibiotics during the study. However, study-specific ranges were defined. The tylosin quality control range subsequently established by the NCCLS for ATCC 29212 was 0.5-4 mg/L, 13 with which the range determined by the study-specific calculations conformed, thus supporting the validity of the method. Field strains. The distribution of MICs for field strains isolated during the first and second year of study for each of the growth promoters is shown in Table 3 , in which data from each country were combined for each of the seven antibiotics. The modes in these distributions were mostly apparent, and the breakpoints (mg/L) based on them were: avilamycin: >16; avoparcin: >8; bacitracin: >8; flavophospholipol: >32; spiramycin: >8; tylosin: >8; virginiamycin: >8 mg/L. The distribution of bacitracin MICs had three separate modes: the chosen breakpoint related to the first of these. A small proportion of isolates had flavophospholipol MICs of £32 mg/L, and these were considered to represent the wild-type susceptible population. Strains were commonly resistant to bacitracin and flavophospholipol but susceptible to avoparcin.
There were differences in resistance between samples taken in year 1 and year 2 following the withdrawal of bacitracin, virginiamycin, tylosin and spiramycin. With the exception of bacitracin, the prevalence of resistance decreased significantly by the second sample point. The prevalence of resistance to avilamycin increased while that of flavophospholipol was unchanged.
The prevalence of resistance for chicken and pig isolates for year 1 and year 2 for each of the countries is shown in Table 4 . Results were similar in isolates from pigs and chickens for compounds other than avilamycin, to which isolates from pigs were less often resistant. Comparison of the results by country showed that Swedish isolates had a lower incidence of resistance to the compounds tested except for flavophospholipol and bacitracin, and that avoparcin resistance was uncommon in all countries sampled. Associated resistance. The incidence of associated resistance between the agents is shown in Table 5 , which includes results for tylosin but not spiramycin, since these were virtually identical. Resistance was very common throughout for flavophospholipol and bacitracin, so statistical analysis was not included for these compounds. The clearest correlations were between virginiamycin and macrolides: virginiamycin-resistant isolates were significantly more likely to be resistant to macrolides than were virginiamycinsusceptible isolates, and macrolide-resistant isolates were more often resistant to virginiamycin than were macrolide-susceptible isolates. Avilamycin-resistant isolates were more often resistant to avoparcin, tylosin and virginiamycin. Only 63 isolates (1.5%) were resistant to virginiamycin, macrolides and avoparcin.
Discussion
Despite the unexpected withdrawal of EU authorization for four of the growth promoters, we were able to reach valid conclusions on the distribution of MICs of growth-promoting antibiotics for E. faecium isolated from food animals in Europe. Since Council Regulation 2821/98 (17.12.98) requiring the removal came into effect from 1 July 1999 (between the two sample points), the results also gave interesting information on the early effects of such a change on the susceptibility of these organisms.
By plotting the MIC distributions of each compound and combining the data from isolates obtained in the different countries in the way currently used by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), it was in each case possible to identify apparent wild-type populations-that is, a group of organisms without acquired resistance mechanisms. Interestingly, the modal MIC for each antibiotic for such populations was around 1-2 mg/L, although for flavophospholipol it seems possible that such low MICs for a very few isolates may have been aberrant, or that the results were correct but very unusual for the species. In fact, it has been shown that E. faecium is seldom susceptible to the substance, although E. faecalis is susceptible.
14 For avoparcin, whose use had been discontinued in all of the countries approximately a year before our study started, the prevalence of resistance was low and about 95% of isolates were in this wild-type group. Indeed, in Sweden, where avoparcin had not been used since 1986, all isolates had wild-type susceptibility, as did all isolates from pigs in Spain. Finally, the very large majority of isolates from pigs were of wild-type susceptibility to avilamycin, perhaps because the compound is not widely used in this species.
For most of the compounds the distribution of MICs was clearly bimodal or, in the case of bacitracin, trimodal. It was therefore relatively easy in each case to allocate microbiological MIC breakpoints in distribution troughs, and where NCCLS human clinical breakpoints were available (glycopeptide, macrolide, streptogramin) they were similar, except for glycopeptides where our breakpoint for avoparcin (>8 mg/L) was lower that the NCCLS equivalent for vancomycin ( ‡32 mg/L). The studyspecific breakpoints were used to calculate the prevalence of microbiological resistance. In the first year this was of the order of 30-50% for the two macrolides and virginiamycin. However, there were considerable differences between countries. In Sweden, where growth-promoting antibiotics had not been used since 1986, more than 85% of isolates were susceptible to all the agents except flavophospholipol (see above) and bacitracin, for which, however, high-level resistance (MICs ‡ 128 mg/L) was uncommon. Virginiamycin resistance in Denmark was low at both sample points, perhaps as a result of the unilateral removal of this compound 6 months before the study began. Unfortunately, quantitative antimicrobial consumption data for the host species were neither available for the countries nor for the individual farms from which the isolates originated. Such data would have been helpful in interpreting geographic variation.
The removal of virginiamycin, spiramycin, bacitracin and tylosin as growth promoters (1 July 1999)-just 3 months before the start of sampling for year 2-apparently resulted in rapid changes in the prevalence of susceptible strains, although the results must be interpreted with caution, given that sampling was in only two time frames. However, the rapid responses to removal were consistent with those reported by others for Denmark, 1, 15 and suggests instability of the resistant E. faecium population in the absence of selection. Results for year 2 were generally consistent with the removal, in that resistance rates were significantly lower for the newly discontinued compounds virginiamycin, spiramycin and tylosin (despite the latter's continued availability for therapeutic purposes). For bacitracin, despite an apparent shift from high to intermediate MICs, there was no overall change in the prevalence of resistance. Avoparcin resistance rates were already low and remained so with no statistical evidence of change, in keeping with the fact of its earlier removal. Flavophospholipol resistance rates showed no significant change. Finally, resistance rates for avilamycin increased significantly in chickens (but not in pigs). This decrease in susceptibility to avilamycin (not removed) might The breakpoint was set in troughs of MIC distribution except in the case of flavophospholipol, for which a breakpoint three concentrations above the mode was used. Vertically paired figures with different superscripts differ significantly (P < 0.05), while those with identical superscripts do not. have resulted from increase usage in the absence of the proscribed compounds. We were able to detect significant associated resistance between antibiotic classes. For the macrolides and virginiamycin, this could have been cross-resistance based on the shared MLS B mechanism. The only example of multiresistance that might have significance for human medicine-associated resistance to streptogramins, macrolides and glycopeptides-was encountered in only 1.5% of the isolates.
The criteria used for the identification of E. faecium appeared fully supportable, although a very few isolates of E. faecalis may have been included, as suggested by the small number of out-ofrange susceptibility test results. These were too few to affect our conclusions. It is notable that whenever surveys of enterococcal antibiotic susceptibility are performed, the problem of misidentification may arise, despite efforts to avoid it. 16 Although the procedure used for establishment of breakpoints differed in some respects from the protocol recommended by the NCCLS, 12 we believe that we have successfully established provisional parameters which we encourage others to test further. Furthermore, since the MIC results were obtained by the use of the NCCLS method (also now suggested as a reference method by EUCAST), 17 comparisons of our quantitative results with others from studies based on these standards are possible-a goal that has been widely supported. 18 
